Andrea Loehr

2.4k total citations
31 papers, 333 citations indexed

About

Andrea Loehr is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Andrea Loehr has authored 31 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Andrea Loehr's work include PARP inhibition in cancer therapy (18 papers), Prostate Cancer Treatment and Research (11 papers) and Cancer Genomics and Diagnostics (9 papers). Andrea Loehr is often cited by papers focused on PARP inhibition in cancer therapy (18 papers), Prostate Cancer Treatment and Research (11 papers) and Cancer Genomics and Diagnostics (9 papers). Andrea Loehr collaborates with scholars based in United States, United Kingdom and France. Andrea Loehr's co-authors include J. Wagner, H. Lode, Dan Ziegler, Andreas du Bois, Philipp Harter, Alexander Traut, K. Gnauert, M. Kandel, Anne Patsouris and Céline Callens and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Andrea Loehr

29 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Loehr United States	10	167	101	78	65	49	31	333
Robert L. Cohen United States	8	138 0.8×	101 1.0×	38 0.5×	57 0.9×	24 0.5×	9	383
J Janssen Netherlands	7	182 1.1×	83 0.8×	35 0.4×	37 0.6×	37 0.8×	14	327
Dingming Wan China	14	133 0.8×	225 2.2×	32 0.4×	102 1.6×	15 0.3×	56	563
Maria Aparecida Zanichelli Brazil	12	194 1.2×	105 1.0×	28 0.4×	14 0.2×	49 1.0×	28	469
Rosanny Espinal-Witter United States	5	40 0.2×	136 1.3×	35 0.4×	41 0.6×	26 0.5×	6	341
Feng‐Ming Tien Taiwan	12	80 0.5×	105 1.0×	21 0.3×	36 0.6×	25 0.5×	27	351
Xiaowen Zhai China	12	99 0.6×	120 1.2×	35 0.4×	26 0.4×	6 0.1×	66	406
Jun Morita Japan	10	148 0.9×	53 0.5×	121 1.6×	63 1.0×	6 0.1×	36	371
Ricardo Pedrini Cruz Brazil	12	104 0.6×	152 1.5×	89 1.1×	37 0.6×	7 0.1×	23	434
Salih Ibrahem Finland	13	120 0.7×	149 1.5×	25 0.3×	57 0.9×	64 1.3×	22	341

Countries citing papers authored by Andrea Loehr

Since Specialization

Citations

This map shows the geographic impact of Andrea Loehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Loehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Loehr more than expected).

Fields of papers citing papers by Andrea Loehr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Loehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Loehr. The network helps show where Andrea Loehr may publish in the future.

Co-authorship network of co-authors of Andrea Loehr

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Loehr. A scholar is included among the top collaborators of Andrea Loehr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Loehr. Andrea Loehr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bryce, Alan H., Josep M. Piulats, M. Neil Reaume, et al.. (2023). Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.. Journal of Clinical Oncology. 41(6_suppl). 18–18. 10 indexed citations

Petrylak, Daniel P., Simon P. Watkins, & Andrea Loehr. (2022). What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib. Frontiers in Oncology. 12. 951348–951348.

Sautois, Brieuc, Andrea Loehr, Simon P. Watkins, Hélène Schroeder, & Wassim Abida. (2022). A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration. Current Oncology. 29(6). 4178–4184. 1 indexed citations

Patsouris, Anne, Olivier Trédan, Anthony Gonçalvès, et al.. (2021). Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer. 159. 283–295. 27 indexed citations

Tukachinsky, Hanna, Russell W. Madison, Jon Chung, et al.. (2021). Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. Journal of Clinical Oncology. 39(6_suppl). 25–25. 2 indexed citations

Abida, Wassim, David Campbell, Akash Patnaik, et al.. (2020). Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 178–178. 5 indexed citations

Shapiro, Jeremy, Ray McDermott, Josep M. Piulats, et al.. (2019). Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies. Cancer Research. 79(13_Supplement). 727–727. 1 indexed citations

Abida, Wassim, Alan H. Bryce, Nicholas J. Vogelzang, et al.. (2019). Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.. Journal of Clinical Oncology. 37(15_suppl). 5031–5031. 4 indexed citations

Gilson, Clare, Fiona C. Ingleby, Duncan C. Gilbert, et al.. (2019). Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.. Journal of Clinical Oncology. 37(15_suppl). 5019–5019. 5 indexed citations

10.

Patsouris, Anne, Olivier Trédan, Alicia Tran-Dien, et al.. (2019). RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).. Journal of Clinical Oncology. 37(15_suppl). 1092–1092. 23 indexed citations

11.

Grivas, Petros, et al.. (2018). ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 36(15_suppl). TPS4592–TPS4592. 3 indexed citations

12.

Abdulfatah, Eman, et al.. (2018). Prognostic impact of loss of heterozygosity in uterine serous carcinoma. Gynecologic Oncology. 149. 72–72.

13.

Pawlyn, Charlotte, Andrea Loehr, Cody Ashby, et al.. (2018). Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. Leukemia. 32(7). 1561–1566. 34 indexed citations

14.

Patsouris, Anne, Olivier Trédan, L. Campion, et al.. (2018). An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.. Journal of Clinical Oncology. 36(15_suppl). TPS1112–TPS1112. 3 indexed citations

15.

Patsouris, Anne, Cécile Vicier, L. Campion, et al.. (2017). An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. Journal of Clinical Oncology. 35(15_suppl). TPS1117–TPS1117. 12 indexed citations

16.

Smyth, Elizabeth, Andrea Loehr, Thomas Harding, et al.. (2016). Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial. Annals of Oncology. 27. vi220–vi220. 2 indexed citations

17.

Kandel, M., Andrea Loehr, Philipp Harter, et al.. (2005). Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. International Journal of Gynecological Cancer. 15(5). 780–784. 27 indexed citations

18.

Bois, Andreas du, et al.. (2005). A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 94(1). 79–84. 3 indexed citations

19.

Costa, Serban Dan, Gϋnter von Minckwitz, Christian Jackisch, et al.. (2004). TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial. Journal of Clinical Oncology. 22(14_suppl). 825–825. 5 indexed citations

20.

Ziegler, Dan, et al.. (1992). Septicemia in 980 Patients at a University Hospital in Berlin: Prospective Studies During 4 Selected Years Between 1979 and 1989. Clinical Infectious Diseases. 15(6). 991–1002. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact